ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to examine if the combination regimen of ARQ 197 with
erlotinib is active in subjects with locally advanced or metastatic NSCLC with activating
mutation EGFR who progressed on EGFR-TKI monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.